1. Home
  2. STEW vs HRMY Comparison

STEW vs HRMY Comparison

Compare STEW & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SRH Total Return Fund Inc.

STEW

SRH Total Return Fund Inc.

HOLD

Current Price

$16.59

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$26.57

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEW
HRMY
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
STEW
HRMY
Price
$16.59
$26.57
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$46.70
AVG Volume (30 Days)
73.3K
644.8K
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.97
EPS
N/A
2.71
Revenue
N/A
$868,453,000.00
Revenue This Year
N/A
$19.75
Revenue Next Year
N/A
$12.88
P/E Ratio
N/A
$10.12
Revenue Growth
N/A
21.51
52 Week Low
$15.00
$25.52
52 Week High
$18.67
$40.87

Technical Indicators

Market Signals
Indicator
STEW
HRMY
Relative Strength Index (RSI) 28.82 30.23
Support Level N/A $25.71
Resistance Level $18.34 $28.99
Average True Range (ATR) 0.21 0.70
MACD -0.03 0.17
Stochastic Oscillator 5.15 0.61

Price Performance

Historical Comparison
STEW
HRMY

About STEW SRH Total Return Fund Inc.

SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: